Clinical Trials Directory

Trials / Unknown

UnknownNCT01230034

Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria

Randomized, Controlled, PROBE Trial, Evaluating the Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic Patients and Mild to Moderate Hypertension With Microalbuminuria

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
206 (estimated)
Sponsor
University of Pavia · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Numerous clinical and experimental data show that the elective treatment of diabetic nephropathy should be based on drugs that inhibit the renin-angiotensin system (RAS). Albuminuria is a marker of risk not only renal but also cardiovascular and diabetic patients with concomitant non-diabetic nephropathy, on the other hand, drugs blocking the renin-angiotensin system available so far, namely ACE inhibitors and angiotensin antagonists II have proven effective in reducing proteinuria in power even if different therapeutic drug to drug. ACE inhibitors are one of the most known and used treatment options for blocking the renin-angiotensin system in patients with microalbuminuria. Drugs such as enalapril, lisinopril and ramipril are standard therapy in diabetic patients with micro or macroalbuminuria. However, it is still unclear whether their efficacy is, from this point of view, the same or varies from drug to drug. This is particularly true in the diabetic microalbuminuria, a condition in which there is sufficient documentation to prove that ramipril is effective. The main objective of this study was to assess the magnitude and trend of the time and to the antiproteinuric effect of antihypertensive 10-20mg/die imidapril versus ramipril 5-10 mg / day in hypertensive patients with type 2 diabetes and microalbuminuria.

Conditions

Interventions

TypeNameDescription
DRUGRamiprilpill, 5 and 10 mg/day, od, 24 weeks
DRUGImidaprilpill, 10 and 20 mg/day, od, 24 weeks

Timeline

Start date
2010-10-01
Primary completion
2011-06-01
Completion
2011-07-01
First posted
2010-10-28
Last updated
2010-10-28

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT01230034. Inclusion in this directory is not an endorsement.